Phase i study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer

Acta Oncologica

Volumn 49, Issue 8, 2010, Pages 1246-1252

  Andersen, Maria ^a   Schønnemann, Katrine R ^b,c   Yilmaz, Mette ^a   Jensen, Helle A ^b   Vestermark, Lene W ^b   Pfeiffer, Per ^b,c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTRO OESOPHAGEAL CANCER; HISTOLOGY; HUMAN; INFECTION; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 77957129391     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841861003767521     Document Type: Article

References (22)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354-62.
2. Faivre J, Forman D, Esteve J, Gatta G. Survival of patients with oesophageal and gastric cancers in Europe. Eur J Cancer 1998;34:2167-75. (Pubitemid 29036882)
3. Murad AM, Santiago FF, Petroianu A, Rocha RP, Rodrigues MA, Rausch M, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
5. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
6. Janunger KG, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001;40:309-26. (Pubitemid 32588125)
7. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
8. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
9. Dupont J, Jensen HA, Jensen BV, Pfeiffer P. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. Acta Oncol 2007;46:330-5.
10. Schønnemann KR, Jensen HA, Yilmaz M, Jensen BY, Larsen O, Pfeiffer P. Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer. Br J Cancer 2008;99:858-61.
11. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006;24:4991-7.
12. Pronk, L, Vasey PA, Sparreboom A, Reigner B, Planting AS, Gordon RJ, et al. "A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours." Br J Cancer 2000;83:22-9.
13. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol in human xenografts. Clin Can Res 1998;4:1013-9.
14. Pfeiffer P, Hahn P, Jensen HA. Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. Acta Oncol 2003;42:832-6.
15. Le Tourneau C, Lee J, Siu L. Dose escalation methods in phase I cancer clinical trials. J Natl Can 2009;101:708-20.
16. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, et al. Docetaxel, cisplatin and fluorouracil; Docetaxel and cisplatin; and epirubicin, cisplatin and fluorouracil as systematic treatment for advanced gastric carcinoma: A randomized phase II trial of the Swiss group for clinical cancer research. J Clin Oncol 2007;25:3217-23.
17. Sym SJ, Ryu MH, Kang HJ, Lee SS, Chang HM, Lee JL, et al. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. Can Chem Pharm 2009; Nov. 21. [Epub ahead of print].
18. Amarantidis K, Xenidis N, Chelis L, Chiotis A, Tentes A, Chatzaki E, et al. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors. Acta Oncol 2009; Oct. 20. [Epub ahead of print].
19. Evans D, Miner T, Akerman P, Millis R, Jean M, Kennedy T, et al. A phase I study of docetaxel, oxaliplatin and capecitabine in patients with metastatic gastroesophageal cancer. Am J Clin Can 2007;30:346-9.
20. Rivera E, Mejia J, Arun B, Adinin R, Walters R, Brewster A, et al. Phase III study comparing the use of docetaxel on a every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008;112:1455-61.
21. Pfeiffer P, Sørbye H, Ehrsson H, Fokstuen T, Mortensen JP, Baltesgard L, et al. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5 fluorouracil. Ann Oncol 2006;17:252-8.
22. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). ASCO 2009 # LBA4509.